UBS published a research report expecting HKEX (00388.HK) 0.000 (0.000%) Short selling $98.62M; Ratio 14.807% 's 2Q25 NPAT/ revenue to increase 35%/ 30% to $4.3 billion/ $7 billion each, 11%/ 7% higher than market consensus, mainly due to better-than-expected net investment income (NII). The broker anticipated full-year NPAT/ revenue to rise by 16% YoY to $15 billion/ $30 billion.UBS also raised its 2025/ 2026/ 2027 ADT forecasts by 14%/ 9%/ 8% to $218 billion/ $185 billion/ $208 billion, and EPS forecasts by 5%/ 2%/ 4% to $11.9/ $10.5/ $11.5, respectively. Therefore, the broker elevated its target price from $393 to $430, with rating kept at Neutral.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-18 12:25.)Related NewsCICC Predicts HKEX's 2Q25 Earnings to Rise 31% YoY; Rating Kept Outperform